Federal health officials reported that the ultra-rare blood clots reported in six people vaccinated with Johnson & Johnson’s COVID-19 vaccine were found in a very small number of people in Europe vaccinated against AstraZeneca. They say they are similar.
Tuesday usa Pause is recommended Vaccination with J & J vaccine until more information is available on how to treat blood coagulation disorders.
J & J
In after-hours trading on Tuesday, stock prices fell 1.3%, and SVB Leerink analysts pointed out that the “pause” weighed on stock prices.
Health officials said Tuesday that they are looking at vaccine data to better understand why blood clots are occurring, the Centers for Disease Control and Prevention’s Immunization Implementation Advisory Committee said. Emergency meeting Discuss J & J vaccine Wednesday afternoon.. Six cases in the United States were women between the ages of 18 and 48.
The same analyst at SVB Leerink predicts that the Commission has updated its recommendations to state that women under the age of 50 should not be vaccinated.
Women are disproportionately affected by this condition with both the J & J vaccine and the AstraZeneca vaccine.
“If someone encounters this very rare syndrome … the most common way to treat it is to use heparin,” said Dr. Anthony Fauci, president’s chief medical adviser to President Joe Biden. Said in the briefing. “It’s a mistake in this situation because it’s dangerous and can make the situation worse. Therefore, there are clinically relevant reasons for wanting to inform people about this.”
Fauci’s quoted condition was serious, one died in the United States and the other was in serious condition, officials said. It is also a very rare condition that occurs in about 1 in 1 million people shot by Johnson & Johnson.
Coagulopathy, called cerebral venous sinus thrombosis, has been reported only in individuals with low levels of platelets, a condition called thrombocytopenia.
“It’s not just cerebral vein thrombosis and thrombocytopenia that are of great interest here,” said Dr. Peter Marks, director of the Food and Drug Administration’s Center for Biologics Evaluation and Research, in another media briefing. I did. “These two things can happen. It’s what makes the pattern that they happen together, and the pattern is very similar to what was seen in Europe.”
The AstraZeneca vaccine, developed in collaboration with Oxford University, has been approved in the United Kingdom and Europe, and health regulators in some countries have stated that Rare reports of blood clotsIt occurs mainly in women within the first few weeks after vaccination.This is similar to the report occurring in the United States
The Johnson & Johnson and AstraZeneca COVID-19 vaccines are both adenovirus viral vector-based vaccines. J & J’s shot was approved in the United States in February and in the European Union in mid-March, but the company now states that it plans to postpone the deployment of the vaccine in Europe.
“This is a similar mechanism that may occur with other adenovirus vector vaccines,” Marks added. “That is, this is a very rare immune response that occurs after some people have been vaccinated, and that immune response leads to the activation of platelets and these very rare blood clots.”
No cases of trousseau sign of thrombosis have been reported in anyone who received one of Pfizer.
Or Moderna Inc.
Previously there was concern, but the mRNA vaccine Allergic reactions that occur in people who receive those shots..
J & J’s share price has risen 1.3% so far this year, while US-listed AstraZeneca’s share price has fallen 1.6%. Wider S & P 500
It is increasing by 9.9% annually.
Rare blood clots associated with J & J’s COVID-19 shots are similar to the AstraZeneca vaccine problem, FDA officials say
http://www.marketwatch.com/news/story.asp?guid=%7B21005575-02D4-D4B5-4572-D3866BD08427%7D&siteid=rss&rss=1 Rare blood clots associated with J & J’s COVID-19 shots are similar to the AstraZeneca vaccine problem, FDA officials say